Mark R Wieland, MD
Ophthalmology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 34
- 8 carriers
- Offices
- 4
Offices
4 locations · Northern California Retina Vitreous Associates Medical Group, Inc. · 7 clinicians in this group
Looking this up.
Plans that list them
34 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wieland’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
34 of 34 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Original Medicare doctor bills
$3,617,523
Medicare paid this office $3,617,523 for 1,340 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 209 | $1,599,030 | None |
| Injection, aflibercept, 1 mg | 176 | $930,931 | None |
| Injection, aflibercept hd, 1 mg | 48 | $255,181 | None |
| Injection of drug into eye | 389 | $206,027 | $109 |
| Established patient complete exam of visual system | 941 | $157,397 | $113 |
See all 15 services
| Injection, faricimab-svoa, 0.1 mg | 209 | $1,599,030 | None |
| Injection, aflibercept, 1 mg | 176 | $930,931 | None |
| Injection, aflibercept hd, 1 mg | 48 | $255,181 | None |
| Injection of drug into eye | 389 | $206,027 | $109 |
| Established patient complete exam of visual system | 941 | $157,397 | $113 |
| Established patient problem focused exam of visual system | 470 | $143,534 | $89 |
| Imaging of retina | 1,235 | $138,174 | $40 |
| Injection, ranibizumab, 0.1 mg | 52 | $89,884 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 184 | $30,998 | $156 |
| New patient complete exam of visual system | 193 | $26,972 | $140 |
| Removal of recurring cataract in lens capsule using a laser | 19 | $7,506 | $357 |
| Photography of the retina | 130 | $5,296 | $34 |
| New patient visit (45+ min) | 17 | $2,528 | $149 |
| Extended exam of the back part of the eye with retinal drawing | 38 | $766 | $20 |
| Imaging of optic nerve | 18 | $634 | $32 |
Procedures Medicare counted
| Cataract surgery | 19 | More than 43% of doctors who do this |
Who their Medicare patients are
1,340 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 28% · Women 59% · Also on Medicaid 6% · Health risk score 1.27. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 71% · Coronary heart disease 28% · Diabetes 26% · Chronic kidney disease 22% · Atrial fibrillation 20% · Cancer 18% · Heart failure 16% · Depression 11% · COPD 10% · Stroke 7% · Dementia 6%.
The office billed $10,935,149, Medicare allowed $4,613,523 and paid $3,617,523; for 70,905 services of 33 kinds; $2,887,280 of it was for drugs given in the office and $730,243 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,340 | 70,905 | 79 | 1.27 | $10,935,149 | $3,617,523 |
| 2023 | 1,221 | 30,075 | 79 | 1.24 | $9,310,104 | $3,099,095 |
| 2022 | 1,205 | 15,304 | 79 | 1.24 | $8,786,551 | $3,080,144 |
| 2021 | 1,230 | 15,270 | 79 | 1.25 | $8,640,079 | $3,266,148 |
| 2020 | 1,112 | 14,288 | 79 | 1.41 | $7,717,171 | $2,923,353 |
| 2019 | 1,324 | 16,345 | 79 | 1.37 | $7,323,218 | $2,814,320 |
| 2018 | 1,281 | 14,769 | 79 | 1.37 | $5,735,399 | $2,213,327 |
| 2017 | 1,214 | 12,212 | 78 | 1.42 | $4,074,225 | $1,624,797 |
| 2016 | 1,201 | 13,090 | 79 | 1.36 | $3,289,266 | $1,557,451 |
| 2015 | 1,207 | 13,415 | 79 | 1.35 | $3,049,318 | $1,451,355 |
| 2014 | 1,233 | 12,950 | 79 | 1.29 | $2,623,849 | $1,374,940 |
| 2013 | 1,284 | 12,467 | 79 | 1.23 | $2,321,010 | $1,264,335 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Injection, aflibercept, 1 mg | 233 | $1,547,506 | None |
| Injection, faricimab-svoa, 0.1 mg | 82 | $472,601 | None |
| Injection, ranibizumab, 0.1 mg | 102 | $425,132 | None |
| Injection of drug into eye | 379 | $189,279 | $103 |
| Established patient complete exam of visual system | 873 | $143,154 | $107 |
| Imaging of retina | 1,127 | $123,097 | $38 |
| Established patient problem focused exam of visual system | 430 | $119,642 | $85 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 155 | $22,323 | $134 |
| New patient complete exam of visual system | 129 | $17,689 | $137 |
| Removal of recurring cataract in lens capsule using a laser | 22 | $8,731 | $349 |
| Photography of the retina | 193 | $7,874 | $33 |
| Extended exam of the back part of the eye with retinal drawing | 236 | $5,874 | $21 |
| New patient visit (45+ min) | 42 | $5,716 | $136 |
| Imaging of optic nerve | 19 | $679 | $32 |
2022: 15 services
| Injection, aflibercept, 1 mg | 260 | $1,846,468 | None |
| Injection, ranibizumab, 0.1 mg | 108 | $604,412 | None |
| Injection of drug into eye | 377 | $190,973 | $101 |
| Established patient complete exam of visual system | 843 | $134,297 | $106 |
| Imaging of retina | 1,023 | $117,112 | $37 |
| Established patient problem focused exam of visual system | 402 | $93,785 | $83 |
| Injection, faricimab-svoa, 0.1 mg | 13 | $19,700 | None |
| New patient complete exam of visual system | 139 | $17,483 | $126 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 126 | $16,057 | $123 |
| Photography of the retina | 248 | $10,285 | $32 |
| Extended exam of the back part of the eye with retinal drawing | 324 | $8,153 | $21 |
| Removal of recurring cataract in lens capsule using a laser | 19 | $6,754 | $307 |
| Compounded drug, not otherwise classified | 21 | $4,132 | None |
| Long return visit (40+ min) | 18 | $2,401 | $133 |
| 2d ultrasound scan of eye tissue and structures | 12 | $703 | $47 |
2021: 16 services
| Injection, aflibercept, 1 mg | 255 | $1,753,042 | None |
| Injection, ranibizumab, 0.1 mg | 125 | $819,208 | None |
| Injection of drug into eye | 397 | $195,885 | $105 |
| Established patient problem focused exam of visual system | 478 | $156,422 | $86 |
| Established patient complete exam of visual system | 844 | $135,774 | $108 |
| Imaging of retina | 928 | $109,431 | $40 |
| Photography of the retina | 475 | $22,707 | $37 |
| New patient complete exam of visual system | 143 | $18,170 | $127 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 132 | $16,073 | $118 |
| Extended exam of the back part of the eye with retinal drawing | 330 | $8,726 | $22 |
| Compounded drug, not otherwise classified | 29 | $6,091 | None |
| Removal of recurring cataract in lens capsule using a laser | 16 | $6,054 | $336 |
| Long return visit (40+ min) | 11 | $2,086 | $174 |
| New patient visit (45+ min) | 15 | $2,009 | $134 |
| Return visit (30+ min) | 12 | $1,394 | $116 |
| Imaging of optic nerve | 18 | $620 | $33 |
2020: 14 services
| Injection, aflibercept, 1 mg | 190 | $1,389,606 | None |
| Injection, ranibizumab, 0.1 mg | 138 | $924,636 | None |
| Injection of drug into eye | 370 | $155,612 | $90 |
| Established patient problem focused exam of visual system | 423 | $148,765 | $82 |
| Established patient complete exam of visual system | 810 | $126,515 | $103 |
| Imaging of retina | 795 | $92,741 | $38 |
| Photography of the retina | 471 | $26,459 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 123 | $13,171 | $105 |
| New patient visit (45+ min) | 99 | $12,785 | $129 |
| Compounded drug, not otherwise classified | 41 | $9,982 | None |
| Extended exam of the back part of the eye with retinal drawing | 343 | $9,172 | $22 |
| Destruction of leaking blood vessels of retina using laser | 11 | $4,127 | $317 |
| New patient complete exam of visual system | 23 | $3,332 | $145 |
| Imaging of optic nerve | 16 | $633 | $32 |
2019: 17 services
| Injection, aflibercept, 1 mg | 191 | $1,203,629 | None |
| Injection, ranibizumab, 0.1 mg | 161 | $842,854 | None |
| Established patient problem focused exam of visual system | 518 | $172,600 | $82 |
| Established patient complete exam of visual system | 937 | $157,794 | $105 |
| Injection of drug into eye | 411 | $154,484 | $91 |
| Imaging of retina | 955 | $108,613 | $38 |
| Examination of eye by ophthalmoscope with retinal drawing | 578 | $36,239 | $24 |
| Photography of the retina | 542 | $34,864 | $48 |
| New patient visit (45+ min) | 152 | $20,833 | $137 |
| Compounded drug, not otherwise classified | 83 | $15,959 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 155 | $14,637 | $90 |
| Examination of eye by ophthalmoscope with retinal drawing | 197 | $9,173 | $26 |
| Removal of recurring cataract in lens capsule using a laser | 20 | $7,467 | $325 |
| Long return visit (40+ min) | 12 | $1,879 | $125 |
| 2d ultrasound scan of eye tissue and structures | 17 | $1,317 | $53 |
| Short return visit | 12 | $562 | $43 |
| Imaging of optic nerve | 12 | $398 | $33 |
2018: 17 services
| Injection, aflibercept, 1 mg | 125 | $782,980 | None |
| Injection, ranibizumab, 0.1 mg | 107 | $699,120 | None |
| Established patient problem focused exam of visual system | 488 | $159,430 | $79 |
| Established patient complete exam of visual system | 940 | $152,771 | $101 |
| Injection of drug into eye | 341 | $132,043 | $88 |
| Imaging of retina | 909 | $101,870 | $38 |
| Photography of the retina | 547 | $40,504 | $52 |
| Examination of eye by ophthalmoscope with retinal drawing | 486 | $26,083 | $23 |
| Compounded drug, not otherwise classified | 139 | $25,491 | None |
| New patient visit (45+ min) | 181 | $23,906 | $132 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 179 | $15,750 | $82 |
| Examination of eye by ophthalmoscope with retinal drawing | 263 | $11,801 | $25 |
| Destruction of leaking blood vessels of retina using laser | 20 | $8,384 | $311 |
| Removal of recurring cataract in lens capsule using a laser | 23 | $8,156 | $326 |
| 2d ultrasound scan of eye tissue and structures | 20 | $1,923 | $64 |
| Long return visit (40+ min) | 14 | $1,717 | $114 |
| Short return visit | 18 | $560 | $31 |
2017: 17 services
| Injection, aflibercept, 1 mg | 86 | $509,910 | None |
| Injection, ranibizumab, 0.1 mg | 80 | $466,896 | None |
| Established patient problem focused exam of visual system | 481 | $134,301 | $76 |
| Established patient complete exam of visual system | 868 | $133,610 | $101 |
| Injection of drug into eye | 313 | $105,196 | $89 |
| Imaging of retina | 893 | $90,641 | $37 |
| Photography of the retina | 405 | $36,601 | $63 |
| Compounded drug, not otherwise classified | 169 | $29,088 | None |
| New patient visit (45+ min) | 157 | $19,961 | $127 |
| Examination of eye by ophthalmoscope with retinal drawing | 360 | $19,076 | $22 |
| Destruction of leaking blood vessels of retina using laser | 24 | $12,607 | $293 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 139 | $10,774 | $74 |
| Examination of eye by ophthalmoscope with retinal drawing | 192 | $8,853 | $25 |
| Return visit (30+ min) | 96 | $8,334 | $86 |
| Removal of recurring cataract in lens capsule using a laser | 15 | $4,827 | $302 |
| Short return visit | 68 | $2,936 | $40 |
| 2d ultrasound scan of eye tissue and structures | 17 | $1,744 | $76 |
2016: 17 services
| Injection, aflibercept, 1 mg | 84 | $488,895 | None |
| Injection, ranibizumab, 0.1 mg | 53 | $324,912 | None |
| Established patient problem focused exam of visual system | 508 | $152,894 | $78 |
| Established patient complete exam of visual system | 868 | $136,791 | $103 |
| Injection of drug into eye | 335 | $116,278 | $91 |
| Imaging of retina | 892 | $111,079 | $42 |
| Compounded drug, not otherwise classified | 222 | $40,090 | None |
| Photography of the retina | 346 | $36,864 | $74 |
| Examination of eye by ophthalmoscope with retinal drawing | 509 | $28,130 | $23 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 115 | $24,295 | $99 |
| New patient visit (45+ min) | 168 | $21,672 | $129 |
| Examination of eye by ophthalmoscope with retinal drawing | 247 | $11,331 | $25 |
| Destruction of leaking blood vessels of retina using laser | 19 | $8,270 | $318 |
| Removal of recurring cataract in lens capsule using a laser | 14 | $4,344 | $310 |
| Return visit (30+ min) | 29 | $2,787 | $96 |
| 2d ultrasound scan of eye tissue and structures | 18 | $1,905 | $83 |
| Short return visit | 25 | $1,057 | $39 |
2015: 19 services
| Injection, aflibercept, 1 mg | 64 | $380,435 | None |
| Injection, ranibizumab, 0.1 mg | 62 | $310,625 | None |
| Established patient complete exam of visual system | 899 | $144,080 | $104 |
| Established patient problem focused exam of visual system | 454 | $131,446 | $76 |
| Injection of drug into eye | 329 | $123,883 | $94 |
| Imaging of retina | 945 | $110,480 | $42 |
| Unclassified biologics | 203 | $32,248 | None |
| Destruction of leaking blood vessels of retina using laser | 21 | $28,383 | $887 |
| Examination of eye by ophthalmoscope with retinal drawing | 546 | $28,166 | $23 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 132 | $26,367 | $99 |
| Photography of the retina | 276 | $26,236 | $73 |
| New patient visit (45+ min) | 177 | $23,377 | $132 |
| Removal of membrane of retina | 14 | $15,048 | $1,075 |
| Compounded Drug, Not Otherwise Classified | 143 | $11,734 | $55 |
| Destruction of growth of retina using a laser | 21 | $10,992 | $478 |
| Examination of eye by ophthalmoscope with retinal drawing | 134 | $6,171 | $24 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 16 | $4,487 | None |
| Removal of recurring cataract in lens capsule using a laser | 11 | $3,769 | $314 |
| 2d ultrasound scan of eye tissue and structures | 20 | $2,548 | $88 |
2014: 18 services
| Injection, ranibizumab, 0.1 mg | 63 | $332,941 | None |
| Injection, aflibercept, 1 mg | 50 | $323,838 | None |
| Established patient complete exam of visual system | 923 | $145,997 | $104 |
| Established patient problem focused exam of visual system | 452 | $119,240 | $75 |
| Injection of drug into eye | 322 | $111,449 | $93 |
| Imaging of retina | 946 | $107,302 | $42 |
| Unclassified biologics | 223 | $35,093 | None |
| Destruction of leaking blood vessels of retina using laser | 26 | $29,808 | $932 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 144 | $29,554 | $101 |
| Photography of the retina | 324 | $26,699 | $74 |
| New patient visit (45+ min) | 189 | $26,314 | $139 |
| Destruction of growth of retina using a laser | 38 | $20,806 | $462 |
| Examination of eye by ophthalmoscope with retinal drawing | 352 | $12,698 | $23 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 22 | $6,489 | None |
| Removal of recurring cataract in lens capsule using a laser | 16 | $5,649 | $314 |
| Examination of eye by ophthalmoscope with retinal drawing | 96 | $2,876 | $25 |
| 2d ultrasound scan of eye tissue and structures | 16 | $2,068 | $86 |
| Imaging of optic nerve | 12 | $497 | $41 |
2013: 17 services
| Injection, ranibizumab, 0.1 mg | 74 | $340,323 | None |
| Injection, aflibercept, 1 mg | 37 | $177,429 | None |
| Established patient complete exam of visual system | 974 | $151,573 | $102 |
| Established patient problem focused exam of visual system | 473 | $119,588 | $75 |
| Injection of drug into eye | 346 | $110,193 | $90 |
| Imaging of retina | 940 | $105,257 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 200 | $42,672 | $102 |
| Unclassified biologics | 249 | $40,381 | None |
| Photography of the retina | 414 | $32,357 | $69 |
| New patient visit (45+ min) | 232 | $30,451 | $131 |
| Destruction of growth of retina using a laser | 47 | $26,880 | $472 |
| Destruction of leaking blood vessels of retina using laser | 23 | $25,744 | $919 |
| Examination of eye by ophthalmoscope with retinal drawing | 238 | $6,435 | $23 |
| Injection, triamcinolone acetonide, preservative free, 1 mg | 21 | $4,624 | None |
| Removal of recurring cataract in lens capsule using a laser | 11 | $3,451 | $314 |
| 2d ultrasound scan of eye tissue and structures | 19 | $1,722 | $86 |
| Examination of eye by ophthalmoscope with retinal drawing | 57 | $1,389 | $24 |
Medicaid work
$55,561 in 2024
Medicaid paid $55,561 for 772 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 46 | $23,681 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 202 | $21,579 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 203 | $5,266 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 321 | $5,035 |
| 2024 | 772 | 4 | 34 | $55,561 |
| 2023 | 980 | 4 | 36 | $83,887 |
| 2022 | 898 | 4 | 29 | $100,645 |
| 2021 | 624 | 4 | 25 | $27,782 |
| 2020 | 469 | 4 | 21 | $14,890 |
| 2019 | 473 | 4 | 24 | $15,744 |
| 2018 | 275 | 4 | 18 | $3,479 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 110 | $50,190 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 223 | $21,899 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 435 | $7,744 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 212 | $4,054 |
2022
| Aflibercept injection | 132 | $57,686 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 258 | $33,980 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 359 | $5,722 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 149 | $3,257 |
2021
| Aflibercept injection | 82 | $16,893 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 177 | $9,095 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 210 | $992 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 155 | $802 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 160 | $12,561 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 150 | $999 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 146 | $957 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 13 | $373 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 129 | $13,363 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 151 | $1,294 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 180 | $1,014 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 13 | $73 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 12 | $1,514 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 161 | $1,138 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 87 | $754 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 15 | $73 |
Drugs they prescribed that Part D paid
$10,171
Pharmacies billed $10,171 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 119) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
79 generic and 40 brand-name prescriptions · $10,171 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Latanoprost | 31 | $571 | $18 |
| Timolol Maleate | 25 | $383 | $15 |
| Ketorolac Tromethamine | 11 | $71 | $6 |
Year by year
| 2024 | 119 | 31 | 0% (0) | 34% | $10,171 |
| 2023 | 188 | 41 | 0% (0) | 45% | $17,805 |
| 2022 | 230 | 54 | 0% (0) | 61% | $35,131 |
| 2021 | 257 | 80 | 0% (0) | 64% | $42,213 |
| 2020 | 282 | 89 | 0% (0) | 57% | $43,876 |
| 2019 | 393 | 112 | 0% (0) | 49% | $48,079 |
| 2018 | 386 | 132 | None | 46% | $61,014 |
| 2017 | 373 | 131 | 0% (0) | 55% | $50,294 |
| 2016 | 414 | 136 | None | 57% | $59,289 |
| 2015 | 374 | 133 | None | 51% | $38,687 |
| 2014 | 280 | 99 | None | None | $24,228 |
| 2013 | 337 | 113 | 4% (14) | 53% | $28,665 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Lumigan | 14 | $4,656 | $333 |
| Difluprednate | 13 | $2,059 | $158 |
| Latanoprost | 51 | $1,003 | $20 |
| Timolol Maleate | 33 | $646 | $20 |
| Prednisolone Acetate | 11 | $601 | $55 |
| Atropine Sulfate | 14 | $434 | $31 |
2022: 7 drugs
| Lumigan | 21 | $6,609 | $315 |
| Simbrinza | 14 | $2,861 | $204 |
| Difluprednate | 13 | $2,036 | $157 |
| Timolol Maleate | 37 | $1,974 | $53 |
| Latanoprost | 52 | $1,297 | $25 |
| Prednisolone Acetate | 19 | $1,131 | $60 |
| Atropine Sulfate | 13 | $546 | $42 |
2021: 5 drugs
| Durezol | 30 | $9,499 | $317 |
| Prednisolone Acetate | 41 | $2,338 | $57 |
| Latanoprost | 49 | $2,137 | $44 |
| Timolol Maleate | 32 | $1,748 | $55 |
| Dorzolamide | 13 | $324 | $25 |
2020: 5 drugs
| Durezol | 30 | $9,403 | $313 |
| Prednisolone Acetate | 44 | $2,745 | $62 |
| Latanoprost | 41 | $1,532 | $37 |
| Neomycin-Polymyxin-Dexameth | 21 | $558 | $27 |
| Timolol Maleate | 20 | $321 | $16 |
2019: 12 drugs
| Durezol | 20 | $5,672 | $284 |
| Travatan Z | 11 | $4,570 | $415 |
| Combigan | 16 | $4,201 | $263 |
| Lotemax | 12 | $3,939 | $328 |
| Prednisolone Acetate | 45 | $2,877 | $64 |
| Latanoprost | 69 | $2,490 | $36 |
| Brimonidine | 11 | $2,366 | $215 |
| Timolol Maleate | 44 | $2,225 | $51 |
| Neomycin-Polymyxin-Dexameth | 53 | $1,034 | $20 |
| Dorzolamide-Timolol | 21 | $861 | $41 |
| Atropine Sulfate | 14 | $730 | $52 |
| Dorzolamide | 16 | $291 | $18 |
2018: 10 drugs
| Durezol | 22 | $5,510 | $250 |
| Lotemax | 12 | $4,660 | $388 |
| Timolol Maleate | 62 | $4,599 | $74 |
| Restasis | 11 | $4,487 | $408 |
| Combigan | 13 | $3,956 | $304 |
| Travatan Z | 12 | $3,800 | $317 |
| Prednisolone Acetate | 43 | $2,580 | $60 |
| Latanoprost | 71 | $1,943 | $27 |
| Neomycin-Polymyxin-Dexameth | 40 | $639 | $16 |
| Dorzolamide-Timolol | 23 | $541 | $24 |
2017: 8 drugs
| Prolensa | 19 | $5,614 | $295 |
| Prednisolone Acetate | 66 | $4,236 | $64 |
| Lotemax | 11 | $3,549 | $323 |
| Timolol Maleate | 71 | $3,449 | $49 |
| Combigan | 15 | $3,034 | $202 |
| Latanoprost | 53 | $1,239 | $23 |
| Neomycin-Polymyxin-Dexameth | 31 | $592 | $19 |
| Dorzolamide-Timolol | 18 | $447 | $25 |
2016: 9 drugs
| Durezol | 30 | $5,985 | $200 |
| Prednisolone Acetate | 63 | $4,445 | $71 |
| Alphagan P | 22 | $4,356 | $198 |
| Prolensa | 19 | $4,084 | $215 |
| Lumigan | 12 | $3,867 | $322 |
| Timolol Maleate | 56 | $1,429 | $26 |
| Neomycin-Polymyxin-Dexameth | 48 | $916 | $19 |
| Latanoprost | 30 | $684 | $23 |
| Dorzolamide-Timolol | 31 | $519 | $17 |
2015: 12 drugs
| Prolensa | 20 | $5,219 | $261 |
| Alphagan P | 20 | $4,388 | $219 |
| Restasis | 11 | $4,105 | $373 |
| Prednisolone Acetate | 53 | $3,432 | $65 |
| Durezol | 15 | $2,617 | $174 |
| Lastacaft | 11 | $2,226 | $202 |
| Neomycin-Polymyxin-Dexameth | 66 | $1,268 | $19 |
| Acetazolamide | 11 | $919 | $84 |
| Brimonidine | 14 | $568 | $41 |
| Dorzolamide-Timolol | 31 | $556 | $18 |
| Latanoprost | 30 | $479 | $16 |
| Timolol Maleate | 33 | $255 | $8 |
2014: 8 drugs
| Restasis | 15 | $5,538 | $369 |
| Prednisolone Acetate | 37 | $2,225 | $60 |
| Acetazolamide | 13 | $1,695 | $130 |
| Alphagan P | 11 | $1,602 | $146 |
| Neomycin-Polymyxin-Dexameth | 44 | $936 | $21 |
| Dorzolamide-Timolol | 29 | $619 | $21 |
| Latanoprost | 22 | $399 | $18 |
| Timolol Maleate | 21 | $200 | $10 |
2013: 10 drugs
| Lumigan | 17 | $4,712 | $277 |
| Alphagan P | 22 | $3,480 | $158 |
| Durezol | 14 | $2,153 | $154 |
| Prednisolone Acetate | 52 | $1,044 | $20 |
| Acetazolamide | 14 | $987 | $71 |
| Neomycin-Polymyxin-Dexameth | 46 | $958 | $21 |
| Latanoprost | 24 | $619 | $26 |
| Timolol Maleate | 25 | $445 | $18 |
| Dorzolamide-Timolol | 14 | $410 | $29 |
| Hydrocodone-Acetaminophen | 13 | $43 | $3 |
Money from drug and device companies
$457 in 2025
| 2025 | 6 | 16 | None | $457 |
| 2024 | 2 | 8 | None | $338 |
| 2023 | 5 | 22 | $9,038 | $10,427 |
| 2022 | 6 | 18 | $2,518 | $3,522 |
| 2021 | 6 | 15 | $5,753 | $6,136 |
| 2020 | 5 | 15 | $5,816 | $5,978 |
| 2019 | 7 | 35 | $21,143 | $23,721 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Eylea Hd | $236 | 8 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $82 | 3 payments
|
| Genentech USA | Vabysmo | $70 | 2 payments
|
| Amgen | Tepezza | $29 | 1 payment
|
| Apellis Pharmaceuticals | Syfovre | $23 | 1 payment
|
| Lumibird Medical | None | $18 | 1 payment
|
See all 16 published payments
| Regeneron Healthcare Solutions | Meals · 2025-12-17 | Eylea Hd | $23 |
| Regeneron Pharmaceuticals | Meals · 2025-10-13 | Eylea Hd | $33 |
| Genentech USA | Meals · 2025-10-07 | Vabysmo | $35 |
| Regeneron Healthcare Solutions | Meals · 2025-10-01 | Eylea Hd | $37 |
| Apellis Pharmaceuticals | Meals · 2025-08-27 | Syfovre | $23 |
| Regeneron Healthcare Solutions | Meals · 2025-07-08 | Eylea Hd | $40 |
| Regeneron Healthcare Solutions | Meals · 2025-06-03 | Eylea Hd | $39 |
| Regeneron Healthcare Solutions | Meals · 2025-05-28 | Eylea Hd | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-05-28 | Eylea Hd | $1 |
| Regeneron Pharmaceuticals | Meals · 2025-05-21 | Eylea Hd | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-05-15 | Eylea Hd | $35 |
| Regeneron Healthcare Solutions | Meals · 2025-04-09 | Eylea Hd | $31 |
| Regeneron Pharmaceuticals | Meals · 2025-03-10 | Eylea Hd | $25 |
| Amgen | Meals · 2025-02-26 | Tepezza | $29 |
| Genentech USA | Meals · 2025-02-10 | Vabysmo | $35 |
| Lumibird Medical | Meals · 2025-02-04 | None | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $338
| Genentech USA | Vabysmo | $243 | 5 payments
|
| Regeneron Healthcare Solutions | Eylea Hd | $95 | 3 payments
|
2023: $10,427
| Genentech USA | Susvimo | $8,592 | 10 payments
|
| Regeneron Healthcare Solutions | Eylea | $1,622 | 6 payments
|
| Regeneron Pharmaceuticals | Eylea | $98 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $84 | 3 payments
|
| AbbVie | Ozurdex | $31 | 1 payment
|
2022: $3,522
| Regeneron Healthcare Solutions | Eylea | $1,863 | 9 payments
|
| Genentech USA | Susvimo | $883 | 5 payments
|
| Roche Products | Susvimo | $600 | 1 payment
|
| Genentech | Susvimo | $135 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea | $23 | 1 payment
|
| Alimera Sciences | Iluvien | $19 | 1 payment
|
2021: $6,136
| Genentech | None | $4,710 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $1,089 | 3 payments
|
| Genentech USA | Lucentis | $244 | 6 payments
|
| EyePoint Pharmaceuticals US | Yutiq | $45 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Lotemax Sm | $27 | 2 payments
|
| Optos | Panoramic Ophthalmoscope | $21 | 1 payment
|
2020: $5,978
| Regeneron Healthcare Solutions | Eylea | $4,678 | 6 payments
|
| Genentech | Lucentis | $1,173 | 2 payments
|
| Genentech USA | Lucentis | $85 | 5 payments
|
| Novartis Pharmaceuticals | Beovu | $23 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $23,721
| Genentech | Lucentis | $13,635 | 8 payments
|
| Regeneron Healthcare Solutions | Eylea | $4,215 | 5 payments
|
| F. Hoffmann-La Roche AG | Lucentis | $3,642 | 4 payments
|
| Novartis Pharmaceuticals | Beovu | $1,155 | 12 payments
|
| Allergan | None | $525 | 2 payments
|
| Genentech USA | Lucentis | $443 | 3 payments
|
| Hoffmann-La Roche | Non-Covered Product | $107 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2020 | Their institution | $274,722 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2019 | Their institution | $164,083 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2022 | Their institution | $124,862 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2023 | Their institution | $119,827 |
| Genentech, Inc. · Va2 Phiii · 2020 | Their institution | $114,531 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2021 | Their institution | $96,209 |
| Genentech, Inc. · Va2 Phiii · 2021 | Their institution | $94,956 |
| Genentech, Inc. · Lucentis Fsv4 Lad Amd Ladder · 2019 | Their institution | $91,563 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2023 | Their institution | $91,350 |
| Novartis Pharmaceuticals Corporation · An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Macular Edema Secondary To Branch Retinal Vein Occlusi · 2020 | Their institution | $76,390 |
| Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2019 | Their institution | $75,975 |
| Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2020 | Their institution | $71,505 |
| Genentech, Inc. · Port Delivery System for Ranibizumab · 2020 | Their institution | $65,070 |
| Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2020 | Their institution | $53,688 |
| Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2019 | Their institution | $53,192 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2021 | Their institution | $45,472 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2020 | Their institution | $44,718 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2022 | Their institution | $43,620 |
| Genentech, Inc. · Port Delivery System for Ranibizumab · 2019 | Their institution | $42,781 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2025 | Their institution | $42,102 |
| Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2022 | Their institution | $38,157 |
| Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2022 | Their institution | $34,482 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2024 | Their institution | $34,357 |
| Genentech, Inc. · Lucentis Fsv4 Lad Amd Ladder · 2020 | Their institution | $33,703 |
| Genentech, Inc. · Va2 Phiii · 2019 | Their institution | $33,174 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2020 | Their institution | $31,706 |
| Novartis Pharmaceuticals Corporation · An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Macular Edema Secondary To Branch Retinal Vein Occlusion (Raptor) · 2021 | Their institution | $30,773 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2021 | Their institution | $28,730 |
| Novartis Pharmaceuticals Corporation · A Multicenter Randomized Double Masked Phase 3a Study To Assess Safety and Efficacy of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks in Patients With Neovascular Age Related Macular Degeneration Namd With Persistent Retinal Fluid · 2022 | Their institution | $25,966 |
| Genentech, Inc. · Port Delivery System of Ranizibumab Extension Study · 2021 | Their institution | $24,705 |
| Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2023 | Their institution | $24,433 |
| Genentech, Inc. · Port Delivery System of Ranibizumab Extension Study · 2025 | Their institution | $22,465 |
| Genentech, Inc. · Port Delivery System for Ranibizumab · 2021 | Their institution | $21,914 |
| Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2021 | Their institution | $21,138 |
| Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2022 | Their institution | $17,500 |
| Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2024 | Their institution | $17,493 |
| Alexion Pharmaceuticals, Inc. · A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (Alxn2040) in Patients With Geographic Atrophy (Ga) Secondary To Age Related Macular Degeneration (Amd) · 2024 | Their institution | $16,654 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2019 | Their institution | $16,140 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2019 | Their institution | $13,044 |
| Genentech, Inc. · Va2 Phiii · 2022 | Their institution | $12,558 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2021 | Their institution | $12,095 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2021 | Their institution | $11,971 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2023 | Their institution | $11,347 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2024 | Their institution | $10,564 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2020 | Their institution | $9,785 |
| F. Hoffmann-La Roche AG · Management of Ocular Adverse Events of Special Interest in Patients Implanted With the Port Delivery System With Ranibizumab Pds · 2022 | This clinician | $8,909 |
| Novartis Pharmaceuticals Corporation · An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Macular Edema Secondary To Branch Retinal Vein Occlusi · 2019 | Their institution | $7,949 |
| Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2025 | Their institution | $7,922 |
| Genentech, Inc. · Pre-Clinical9112020 · 2020 | Their institution | $7,030 |
| Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2021 | Their institution | $5,904 |
| Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2022 | Their institution | $5,668 |
| Genentech, Inc. · Port Delivery System for Ranibizumab · 2022 | Their institution | $4,500 |
| F. Hoffmann-La Roche AG · The Port Delivery System With Ranibizumab - A New Paradigm for Long-Acting Retinal Drug Delivery · 2022 | This clinician | $4,454 |
| F. Hoffmann-La Roche AG · Pds Phase 3 Archway · 2021 | This clinician | $4,064 |
| F. Hoffmann-La Roche AG · Management of Ocular Adverse Events of Special Interest in Patients Implanted With the Port Delivery System With Ranibizumab Pds · 2021 | This clinician | $3,910 |
| Genentech, Inc. · Pre-Clinical9162020 · 2020 | Their institution | $1,163 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2022 | Their institution | $161 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2023 | Their institution | $161 |
| Novartis Pharmaceuticals Corporation · A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Diabetic Macular Edema · 2023 | Their institution | $111 |
| Novartis Pharmaceuticals Corporation · A Randomized Double-Masked, Phase III Study Assessing Brolucizumab Intravitreal Injections Versus Aflibercept in Patients With Visual Impairment Due To Macular Edema (Me) Secondary To Central Retinal Vein Occlusion (Crvo) · 2024 | Their institution | $107 |
| Novartis Pharmaceuticals Corporation · An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due To Macular Edema Secondary To Branch Retinal Vein Occlusi · 2022 | Their institution | $7 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1134114382
- Licence
- CA 00A48482
- Trained
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University, 1985
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A484821
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 2485 Hospital Dr, Suite 200, Mountain View, CA, 94040
- NPI first listed
- 2005-09-14
- NPI last updated
- 2017-12-14
This is when the NPI record was last certified, not a medical board exam.